BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28846491)

  • 1. Human papilloma virus vaccine for low and middle income countries: A step too soon?
    Jindal HA; Kaur A; Murugan S
    Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus: science and technologies for the elimination of cervical cancer.
    Bosch FX
    Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
    Moss JL; Reiter PL; Brewer NT
    Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical cancer and HPV vaccines in developing countries.
    Karimi Zarchi M; Behtash N; Chiti Z; Kargar S
    Asian Pac J Cancer Prev; 2009; 10(6):969-74. PubMed ID: 20192568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papilloma virus vaccines: need to be introduced in India.
    Verma R; Khanna P
    Hum Vaccin Immunother; 2013 Jan; 9(1):97-9. PubMed ID: 23108360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
    Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
    BMC Med; 2011 May; 9():54. PubMed ID: 21569406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries.
    Simonella L; Canfell K
    Vaccine; 2015 Jan; 33(1):34-51. PubMed ID: 25171843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV Vaccines: today and in the Future.
    Moscicki AB
    J Adolesc Health; 2008 Oct; 43(4 Suppl):S26-40. PubMed ID: 18809143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].
    Monsonego J
    Presse Med; 2007 Apr; 36(4 Pt 2):640-66. PubMed ID: 17350792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.